Tiziana Reports Consistent Brain Inflammation Reduction in Third MSA Patient Treated with Intranasal Foralumab
TLSA is trading near its 52-week low of $0.866 (10.0% above the low) on light trading volume (0.1× avg).
Summary
Tiziana announced PET imaging results from the third MSA patient in its Phase 2 trial of intranasal foralumab, showing up to a 34% reduction in brain inflammation—consistent with the first two patients. The reproducible signal supports the drug's potential in a disease with no approved therapies.
Key Events · Product Development and Regulatory · TLSA
-
Third MSA Patient Shows Consistent Inflammation Reduction
Quantitative PET imaging revealed up to a 34% reduction in SUV and a 26% reduction in SUVR in the basal ganglia and cerebellar white matter, closely matching the ~35% SUV and 24% SUVR reductions seen in the first two patients.
-
Reproducible Signal Across Patients
The consistency of PET findings across three patients reinforces evidence of biological activity for intranasal foralumab in dampening neuroinflammation in MSA, a disease with no approved disease-modifying treatments.
-
Next Steps: Further Validation Planned
Tiziana plans to continue evaluating intranasal foralumab in additional patients to further validate these findings and better characterize the therapy's potential in MSA.
Analysis · TLSA · Life Sciences
The third MSA patient demonstrated up to a 34% reduction in neuroinflammation on PET imaging, closely mirroring the ~35% and 24% reductions observed in the first two patients. Reproducibility across patients strengthens the case that intranasal foralumab has real biological activity in a disease with no approved treatments. While this is early-stage data, consistency is what moves a clinical program from 'interesting signal' to 'potentially real drug.'
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.5M. The 52-week trading range was $0.87 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.